key: cord-0760916-u8rhmms6
authors: Nesseler, Nicolas; Fadel, Guillaume; Mansour, Alexandre; Para, Marylou; Falcoz, Pierre-Emmanuel; Mongardon, Nicolas; Porto, Alizée; Bertier, Astrid; Levy, Bruno; Cadoz, Cyril; Guinot, Pierre-Grégoire; Fouquet, Olivier; Fellahi, Jean-Luc; Ouattara, Alexandre; Guihaire, Julien; Ruggieri, Vito-Giovanni; Gaudard, Philippe; Labaste, François; Clavier, Thomas; Brini, Kais; Allou, Nicolas; Lacroix, Corentin; Chommeloux, Juliette; Lebreton, Guillaume; Matthay, Michael A.; Provenchere, Sophie; Flécher, Erwan; Vincentelli, André
title: Extracorporeal Membrane Oxygenation for Respiratory Failure Related to COVID-19: A Nationwide Cohort Study
date: 2022-03-29
journal: Anesthesiology
DOI: 10.1097/aln.0000000000004168
sha: ff260093fa7e771e195ea2e8f51d4a22c6544a8c
doc_id: 760916
cord_uid: u8rhmms6

Despite expanding use, knowledge on extracorporeal membrane oxygenation support during the COVID-19 pandemic remains limited. The objective was to report characteristics, management, and outcomes of patients receiving extracorporeal membrane oxygenation with a diagnosis of COVID-19 in France and to identify pre-extracorporeal membrane oxygenation factors associated with in-hospital mortality. A hypothesis of similar mortality rates and risk factors for COVID-19 and non–COVID-19 patients on venovenous extracorporeal membrane oxygenation was made. METHODS: The Extracorporeal Membrane Oxygenation for Respiratory Failure and/or Heart failure related to Severe Acute Respiratory Syndrome-Coronavirus 2 (ECMOSARS) registry included COVID-19 patients supported by extracorporeal membrane oxygenation in France. This study analyzed patients included in this registry up to October 25, 2020, and supported by venovenous extracorporeal membrane oxygenation for respiratory failure with a minimum follow-up of 28 days after cannulation. The primary outcome was in-hospital mortality. Risk factors for in-hospital mortality were analyzed. RESULTS: Among 494 extracorporeal membrane oxygenation patients included in the registry, 429 were initially supported by venovenous extracorporeal membrane oxygenation and followed for at least 28 days. The median (interquartile range) age was 54 yr (46 to 60 yr), and 338 of 429 (79%) were men. Management before extracorporeal membrane oxygenation cannulation included prone positioning for 411 of 429 (96%), neuromuscular blockage for 419 of 427 (98%), and NO for 161 of 401 (40%). A total of 192 of 429 (45%) patients were cannulated by a mobile extracorporeal membrane oxygenation unit. In-hospital mortality was 219 of 429 (51%), with a median follow-up of 49 days (33 to 70 days). Among pre-extracorporeal membrane oxygenation modifiable exposure variables, neuromuscular blockage use (hazard ratio, 0.286; 95% CI, 0.101 to 0.81) and duration of ventilation (more than 7 days compared to less than 2 days; hazard ratio, 1.74; 95% CI, 1.07 to 2.83) were independently associated with in-hospital mortality. Both age (per 10-yr increase; hazard ratio, 1.27; 95% CI, 1.07 to 1.50) and total bilirubin at cannulation (6.0 mg/dl or more compared to less than 1.2 mg/dl; hazard ratio, 2.65; 95% CI, 1.09 to 6.5) were confounders significantly associated with in-hospital mortality. CONCLUSIONS: In-hospital mortality was higher than recently reported, but nearly half of the patients survived. A high proportion of patients were cannulated by a mobile extracorporeal membrane oxygenation unit. Several factors associated with mortality were identified. Venovenous extracorporeal membrane oxygenation support should be considered early within the first week of mechanical ventilation initiation.

Nesseler et al.

pandemic demonstrated the value of ECMO support for patients with severe ARDS related to influenza. [2] [3] [4] [5] [6] Additionally, a recent meta-analysis of patients from two major randomized controlled trials on ECMO support in severe ARDS patients showed a significant benefit of the technique for improving both morbidity and mortality. [7] [8] [9] Several early retrospective case series showed encouraging results of ECMO support in COVID-19-related respiratory failure. [10] [11] [12] [13] However, these case series were limited in sample size (fewer than 90 patients) and restricted to few centers. Consequently, the international report from the Extracorporeal Life Support Organization (Ann Arbor, Michigan) registry, gathering 1,035 ECMO patients from 213 centers in 36 countries, was an important landmark. The study showed an estimated in-hospital mortality of less than 40% for critically ill adults with COVID-19 treated with ECMO in a collection of self-selected and experienced centers worldwide. 14 Recently, a similar mortality rate was reported in a multicenter cohort study of 190 critically ill adults with CRITICAL CARE MEDICINE COVID-19 who received ECMO at 35 sites across the United States. 15 In France, 485 ECMO consoles are available in 103 academic or nonacademic, public, or private centers due to the wide interest in the technique in the country. During the first wave of the pandemic, a central system was established to coordinate national ECMO resources in France. Regional coordinators met weekly to check the national availability of consoles and circuits. Specific recommendations and algorithms were issued on ECMO indications and organization in the context of the outbreak (https:// www.iledefrance.ars.sante.fr/system/files/2020-12/038_ ARSIdF-CRAPS_2020-12-02_Doctrine_ECMO.pdf). 16 Collecting data on this initiative is essential to evaluate the results of our organization, to inform clinicians, and to adapt our response to the future developments of the outbreak. Therefore, the goals of our study were (1) to report characteristics, management, and outcomes of patients receiving ECMO with a diagnosis of COVID-19 in France and (2) to identify potentially modifiable variables associated with in-hospital mortality. We hypothesized that the mortality rate and risk factors would be similar for COVID-19 and non-COVID-19 patients on venovenous ECMO.

The ECMOSARS registry was launched in April 2020 (ClinicalTrials.gov Identifier: NCT04397588, Extracorporeal Membrane Oxygenation for Respiratory Failure and/or Heart failure related to Severe Acute Respiratory Syndrome-Coronavirus 2 [ECMOSARS] registry, principal investigators: Nicolas Nesseler and André Vincentelli, date of registration: May 21, 2020) and is currently still recruiting. The registry includes 47 centers, academic or nonacademic, which represent 77% of the ECMO consoles available in France. The registry has been endorsed by the French Society of Thoracic The data were collected by research assistants using an electronic case report form from each patient's medical record. Automatic checks were generated for missing or incoherent data, and additional consistency tests were performed by data managers. The nationwide objective of our registry implied the collection of all available data of ECMO patients in France, including data for some patients already published in retrospective studies or case series. 12, 14, 17 Two studies focused on a specific French area (e.g., the city of Strasbourg or the Greater Paris area), and one study included only a fraction of French patients in an international cohort, which involved only self-selected and experienced centers.

The registry has been approved by the University Hospital of Rennes ethics committee (approval No. 20.43). According to French legislation, written consent is waived because of the study's observational design that does not imply any modification of existing diagnostic or therapeutic strategies. After the information was provided, only non-opposition of patients or their legal representative was obtained for use of the data.

All patients, adults or children, tested positive by reverse transcription-polymerase chain reaction for SARS-CoV2 (nasopharyngeal swabs, sputum, endotracheal aspiration, bronchoalveolar lavage, or stool sample) and/or with a diagnosis of COVID-19 made on chest computed tomography findings and supported by venovenous, venoarterial, or venoarterio-venous ECMO can be included in the registry. Patients or proxies who refused consent were excluded from the study, as were legally protected adults.

The data were collected prospectively in the ECMOSARS registry, except for patients whose ECMO was implanted before April 21, 2020. Those data were collected retrospectively. Collected data included patient characteristics and comorbidities, management of COVID-related ARDS before ECMO cannulation, patient characteristics at ECMO cannulation and the day after, management, complications, and patient outcomes on ECMO (see Supplemental Digital Content 1, table S1, http://links.lww.com/ALN/C809, for the definition of the main variables).

For the current study, we analyzed all patients included in the registry up to October 25, 2020, initially supported by venovenous ECMO for respiratory failure and with a minimum follow-up of 28 days after ECMO cannulation for alive patients.

Our primary outcome was in-hospital mortality. Secondary outcomes were mortality at day 28, mortality at day 90, ECMO-free days, and intensive care unit (ICU)-free days to day 28. ECMO-free days or ICU-free days are composite outcomes that combine survival and ECMO support duration or survival and ICU length of stay. The numbers of ECMO-free days or ICU-free days were calculated as 28 minus the number of days on ECMO or in the ICU during the first 28 days after ECMO cannulation. Patients who died were assigned the worst possible outcome of 0 ECMO-free days or ICU-free days. range for continuous variables. For bivariate comparison between deceased and alive patients, a chi-square test or a Fisher exact test was used for categorical variables, and an independent t test or a Wilcoxon rank sum test was used for continuous variables. Blood gases values and ventilator settings before and after ECMO cannulation were compared using a repeated measures ANOVA model. The ventilatory ratio was defined as [minute ventilation (ml/min) × Paco 2 (mmHg)]/(predicted body weight × 100 × 37.5). 18 A statistical analysis plan was made before accessing the data. No a priori statistical power calculation was conducted. Regarding the primary outcome, no minimum clinically meaningful hazard ratio was defined before data access. In accordance with reviewers' recommendations, modeling and variable selection strategies were modified and are thus considered post hoc analyses. Only pre-ECMO variables were included in these analyses to prevent competing risk bias.

A directed acyclic graph was used to describe the associations between pre-ECMO modifiable exposure variables, patient-related confounders, pre-ECMO hospitalizationrelated confounders, and in-hospital mortality using DAGitty software (Supplemental Digital Content 1, fig. S1, http://links.lww.com/ALN/C809). 19 No variables were analyzed as effect modifiers. Pre-ECMO modifiable exposure variables comprised anticoagulation, antibiotic therapy, antiviral therapy, noninvasive ventilation, selective digestive decontamination, neuromuscular blocking agents, prone position, high-flow oxygen therapy, cannulation mode, inotropes use, vasopressors use, renal replacement therapy, ECMO cannulation, inhaled NO, positive endexpiratory pressure, tidal volume at cannulation, and ventilation duration before ECMO. The set of pre-ECMO confounders sufficient for adjustment comprised patient-related confounders (sex, age, body mass index, diabetes, chronic obstructive pulmonary disease, chronic respiratory failure, congestive heart failure, chronic kidney disease, malignancy, and previous corticotherapy) and pre-ECMO hospitalization-related confounders (septic shock, total bilirubin at cannulation, pH at cannulation, Paco 2 at cannulation, Pao 2 / fractional inspired oxygen tension (Fio 2 ) ratio at cannulation, driving pressure, left ventricular ejection fraction, ventilator-associated pneumonia, and delay from hospitalization to ICU admission).

To estimate hazard ratios between exposure variables and in-hospital mortality, we fitted a univariate and multivariable Cox proportional hazards model including exposure variables and confounders identified using the directed acyclic graph. Four different models were built, for sensitivity analysis (see Supplemental Digital Content 1, table S2, http://links.lww.com/ALN/C809). Model 1 was a univariable Cox model; model 2 was a multivariable Cox model of modifiable exposure variables, adjusted for patient-related confounders; model 3 was a multivariable Cox model of modifiable exposure variables, adjusted for pre-ECMO hospitalization-related confounders; and model 4 was a multivariable Cox model of modifiable exposure variables, fully adjusted for all confounders. Centers were included as a random effect using a γ frailty model. Patients who were still hospitalized were censored at the time of the database lock, and those who were discharged alive were censored at the time of their discharge date. Proportional hazard assumption was assessed using simultaneous time-dependent covariates. To comply with log-linearity assumptions, several continuous variables (body mass index, pH, left ventricular ejection fraction, delay from hospitalization to ICU admission, driving pressure, positive end-expiratory pressure, tidal volume, and ventilation duration before ECMO) were split into categorical variables in accordance with previously published works and guidelines. 8, [20] [21] [22] [23] [24] [25] [26] Multiple imputation was used to account for missing values in variables (Supplemental Digital Content 1, table S3, http://links.lww.com/ALN/C809). We used fully specified chained equations in the SAS multiple imputation procedure (SAS Institute, USA). For continuous variables, the regression method was used to impute missing values, and discriminant function methods were used for binary and categorical variables. Passive imputation was used for the derived variables (body mass index, tidal volume, Pao 2 / Fio 2 ratio, anticoagulation before ECMO, and malignancy), meaning that each variable needed for the calculation was imputed before the calculation of the derived variable. A total of 50 imputed data sets were created and combined using standard between/within-variance techniques. All tests used a two-tailed hypothesis. Statistical significance was achieved for P < 0.05. Statistical analyses were computed with SAS version 9.4 software (SAS Institute, USA).

At the time of the database lock, 38 centers had included 494 patients in the ECMOSARS registry, of whom 462 patients were followed for at least 28 days after ECMO cannulation; 429 patients were initially supported by venovenous ECMO, and 33 were supported by venoarterial ECMO ( fig. 1 ). No patients were initially supported by venoarterio-venous ECMO.

The first venovenous ECMO included in the analysis was implanted on February 25, 2020, and the last venovenous ECMO included in the analysis was implanted on September 17, 2020. Most of the patients (257 [59.9%]) were admitted from another hospital. Venovenous ECMO was cannulated in-hospital by mobile ECMO units in 192 (45%) patients, of whom 79% were transferred subsequently to a referral ECMO center. In total, 13 centers included fewer than 5 patients, 12 centers included between 5 and 10 patients, 5 centers included between 10 and 20 patients, 2 centers included between 20 and 30 patients, 3 centers included between 30 and 40 patients, and 1 center included 124 (26.8%) patients (see Supplemental Digital Content 1, figs. S2 and S3, http://links.lww.com/ALN/C809).

The median age was 54 (46 to 60) years, 79% of the patients were men, and the median body mass index was 30 ( 1 ). Median ventilation duration before ECMO was 5.0 (3.0 to 8.0) days. The median total Sequential Organ Failure Assessment (SOFA) score at cannulation (n = 395) was 9 (8 to 12), and 51% (216 of 422) of the patients had a cardiovascular SOFA score of 3 or higher. The blood lactate level was 1.7 (1.2 to 2.3) mmol/l (n = 366), and 12% (51 of 423) of the patients were on renal replacement therapy. Finally, 99% of the patients met the Berlin ARDS criteria at ECMO cannulation (table 2) .

The ventilation settings at the time of the cannulation and the day after the cannulation are shown in table 3. ECMO cannulation was associated with reduced tidal volume, respiratory rate, and Fio 2 , as well as lower plateau and driving pressures. A tracheostomy was performed in 21% (90 of 424) of the patients. 

In-hospital mortality was 219 of 429 (51%) with a median follow-up of 49 (33 to 70) days (see Supplemental Digital Content 1, fig. S4 , http://links.lww.com/ALN/C809). The extent of missing data across all variables included in the statistical models is described in Supplemental Digital Content 1 (table S3, http://links.lww.com/ALN/C809). Mortality at days 28 and 90 was 42% (180 of 429) and 60% (215 of 357), respectively. At day 28, ventilator-free days (n = 425), ECMO-free days (n = 414), and ICU-free days (n = 412) were 0 (0 to 0), 0 (0 to 14) , and 0 (0 to 0) days, respectively. More male patients died, and they were significantly older (table 1) . At cannulation, pH was significantly lower, and the Paco 2 , the ventilatory ratio, and the serum lactate levels were significantly higher in the patients who ultimately died (table 2) . Patients who died also had a significantly higher 

Nesseler et al.

SOFA score at cannulation, with significantly more patients with a liver (6.0 mg/dl bilirubin or more) and cardiovascular scores of 3 or higher and significantly more patients with renal replacement therapy than patients who survived. While on ECMO, patients who ultimately died experienced significantly more hemorrhagic complications, membrane lung failure, acute kidney injury, and neurologic complications than patients who survived (table 4) .

Among pre-ECMO modifiable exposure variables, neuromuscular blockage use (hazard ratio, 0.286; 95% CI, 0.101 to 0.81) and duration of ventilation (more than 7 days compared to less than 2 days; hazard ratio, 1.74; 95% CI, 1.07 to 2.83) were independently associated with in-hospital mortality (table 5) . Among patient-related and pre-ECMO hospitalization-related confounders, age (per 10-yr increase; hazard ratio, 1.27; 95% CI, 1.07 to 1.50) and total bilirubin at cannulation (6.0 mg/dl or more compared to less than 1.2 mg/dl; hazard ratio, 2.65; 95% CI, 1.09 to 6.5) were both significantly associated with in-hospital mortality. These results remained consistent after sensitivity analysis in two distinct models: (1) modifiable exposure variables and patient-related baseline characteristics and (2) 

Our study reports, at a nationwide level, the characteristics, management, and outcomes of COVID-19 patients treated with venovenous ECMO for respiratory failure. We found an in-hospital mortality of 51%, numerically higher (0) The results are presented as n (%) or median (interquartile range). *The ventilatory ratio is defined as [minute ventilation (ml/min) × Paco 2 (mmHg)]/(predicted body weight × 100 × 37.5). aRDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; Fio 2 , fractional inspired oxygen tension; ICU, intensive care unit; PEEP, positive end-expiratory pressure; SOFa, Sequential Organ Failure assessment; V T , tidal volume.

Nesseler et al.

than that reported in two recent studies of venovenous ECMO use in COVID-19 patients. 14, 15 The international Extracorporeal Life Support Organization study reported an estimated cumulative incidence of in-hospital mortality 90 days after ECMO initiation of 37%. 13 , which is known to be associated with worse outcomes. 24 Our patients were also more likely to have been proned (96% vs. 60% in the Extracorporeal Life Support Organization or 71% in the Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19 cohort) and/or paralyzed before ECMO cannulation (98% vs. 72% or 78%), both suggesting the use of ECMO later in the disease process. Finally, this study included patients from a wide range of both highand low-volume centers, reflecting the broad use of ECMO in France during the COVID-19 pandemic. 9 We found several factors independently associated with in-hospital mortality in our cohort, including older age, liver failure (6 mg/dl bilirubin or more) at ECMO cannulation, and a duration of ventilation before ECMO cannulation of more than 7 days; in contrast, only neuromuscular blocking agent use before ECMO was found as a protective factor. These findings were consistent with previous studies 14, 24, 27, 28 and could be useful to the bedside clinician. First, they emphasize the value of early consideration of ECMO when indicated. This finding is particularly important as it can be easily modifiable at the bedside. In our cohort, 26% of the patients were canulated after 7 days of mechanical ventilation. Thus, the clinicians should be strongly encouraged to consider ECMO within 7 days after mechanical ventilation initiation. Second, these findings emphasize that ECMO support seems less beneficial in the sickest patients, as previously described for non-COVID-19 ARDS patients. 24, 27, 28 In our cohort, liver failure at cannulation appears to be an especially strong marker of severity, which should alert the clinicians before considering ECMO support. Of course, only a limited number of patients presented liver failure, which underlined that the majority of clinicians are already fully aware of the poor results of ECMO support in the sickest patients. Third, the data from this study again emphasize the comparatively poorer outcomes in older patients who received ECMO for COVID-19. Notably, patients of more than 70 yr of age were excluded from the U.S. Study of The results are presented as median (interquartile range). The P values are for bivariate analysis between pre-and post-ECMO. ECMO, extracorporeal membrane oxygenation; Fio 2 , fractional inspired oxygen tension; PEEP, positive end-expiratory pressure; V T , tidal volume.

the Treatment and Outcomes in Critically Ill Patients with COVID-19. 15 Finally, the favorable results in patients in this cohort who received neuromuscular blocking agent before ECMO cannulation are in line with previous work 24 but should be interpreted with caution here as the vast majority of patients in our cohort received neuromuscular blocking agent before ECMO. Indeed, the very few patients who did not receive neuromuscular blocking agent before cannulation must be considered outliers whose management may have been out of the standard of care. 

Nesseler et al.

While on ECMO, patients who ultimately died experienced significantly more hemorrhagic complications, neurologic complications (mainly hemorrhagic stroke), membrane lung failure, and acute kidney injury than patients who survived. We report more frequent bleeding complications than in the U.S. Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19 study (28% vs. 40%) or in the Extracorporeal Life Support Organization study, including cannula site bleeding (18% vs. 7%, respectively), gastrointestinal hemorrhage (6% vs. 3%, respectively), and pulmonary hemorrhage (8% vs. 4%, respectively). Although our definitions of bleeding events were less restrictive, this might be also related to the contemporaneous publication of French guidelines on anticoagulation in COVID-19 patients, which recommended elevated unfractionated heparin targets in ECMO patients after early reports of prothrombotic state in COVID-19 patients. 29 Of note, the ECMO to Rescue Lung Injury in Severe ARDS trial reported 46% of bleeding leading to transfusion. Similarly, we observed a higher proportion of hemorrhagic stroke (9%) than previously reported (2, 4, and 6% in the ECMO to Rescue Lung Injury in Severe ARDS trial, the U.S. Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19, and the Extracorporeal Life Support Organization studies, respectively).

Membrane lung failures were higher than in the Extracorporeal Life Support Organization study (12% vs. 8%), and the higher proportion in the nonsurvivors might reflect the hypercoagulopathy pattern described in the more severe patients. 30 Interestingly, the proportion of acute kidney injury (AKI) requiring renal replacement therapy (35%) was higher than in the Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19 study (22%) but lower than in the Extracorporeal Life Support Organization study (44%) or the ECMO to Rescue Lung Injury in Severe ARDS trial (52%). Nevertheless, as in in the Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19 study, the proportion of AKI was significantly higher in the nonsurvivors, highlighting how the development of AKI might be a turning point in the trajectories of COVID-19 patients on ECMO.

Critically ill patients with COVID-19 have been found at high risk for hospital-acquired infections. 31 In non-ECMO critically ill patients with COVID-19, ventilator-associated pneumonia was found in 25 to 50%, and bacteremia was found in 15 to 34%. 31, 32 However, few data are available in COVID-19 patients on ECMO. We found a high proportion of ventilator-associated pneumonia (51%) and bacteremia while on ECMO (41%). The Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19 study reported 35% of ventilator-associated pneumonia and 18% of other documented infections. A similar proportion of 39% of ventilator-associated pneumonia on ECMO was reported in the ECMO to Rescue Lung Injury in Severe ARDS trial. The discrepancy between our study and other reports remains to be elucidated. One hypothesis might be the difficulty of applying infection control procedures in a context of increased workload and a shortage in healthcare workers related to the pandemic surge. Variations in ventilator-associated pneumonia definition applications and microbiologic sampling methods across ICUs and countries might also explain these differences, and further studies are mandated to explore these questions. In contrast, in our cohort, the cannula site infection proportion (8%) was lower than previously described in non-COVID-19 patients. 8, 33 A high proportion of patients were cannulated by mobile ECMO units in our cohort (45%), similar to the percentage previously reported in the Extracorporeal Life Support Organization study (47%). Cannulation by mobile ECMO unit was not found associated with higher mortality, highlighting the importance of mobile ECMO program to rescue patients hospitalized outside of the referral centers as previously suggested. 34 Of note, cannulation by a mobile ECMO unit was not associated with more cannula site bleeding, but more cannula site infections were observed.

Our study has several strengths. This cohort is one of the largest samples of patients supported by venovenous ECMO for COVID-19-related ARDS published to date. Second, the participating centers represented most of the ECMO sites available in France, giving this study a good representation of the ECMO activity between the end of February and September 2020. Additionally, a central system was established to coordinate national ECMO resources, allowing relocation of consoles and circuits, when needed, in the areas the most affected by the virus. Third, the wide adherence during the pre-ECMO period 

to known medical interventions in ARDS patient management, such as protective ventilation, prone positioning, or neuromuscular blocking agent infusions, must be emphasized. These data strengthen the fact that in our cohort, ECMO support was proposed to highly severe patients as a rescue therapy after adequate management. Fourth, the multicenter design enables generalization of the data. Finally, the database quality was regularly assessed by dedicated data managers. However, there are some limitations. Despite broad representation among French ECMO centers, the cohort did not include all ECMO centers, creating potential selection bias. Within our cohort, a significant proportion (26%) of patients came from a single center in Paris, which is a high-volume ECMO center and is also located in an area that was severely affected by the pandemic. In addition, at the time of the database lock, 34 patients (8%) were still hospitalized, leading to a possible underestimation of the in-hospital mortality. Further, as an observational study relying on patients' medical records, this study might be subject to information bias. There were no specific recommendations on cannulation or management of ECMO, introducing variability in management across the study population. However, because we anticipated regional differences in the burden of the pandemic, as well as expertise disparities between participating centers, centers were included as a random effect using a γ frailty model in the Cox model. Additionally, considering that the vast majority of patients in our cohort received neuromuscular blocking agent before ECMO, we underline that the association found between neuromuscular blocking agent use and survival must be interpreted with caution. Finally, it is worth remembering that our study analyzed only patients already receiving ECMO, and thus the results obtained might not be fully relevant in a general population of severe COVID-19 patients.

In conclusion, this analysis of the ECMOSARS registry provides results and outcomes of COVID-19-related respiratory failure patients supported by venovenous ECMO between February and September 2020 in France. In-hospital mortality was higher than recently reported in a multicenter international cohort, but nearly half of the patients survived. A high proportion of patients were cannulated by mobile ECMO unit without negative impact on mortality. Several factors associated with mortality were identified, which may help to guide future clinical decision-making. In particular, venovenous ECMO support should be considered early, within the first week of mechanical ventilation initiation.

Supported by a grant from the University Hospital of Rennes (Appel à Projets CFTR2; Rennes, France) and by a grant from the Société Française de Chirurgie Thoracique et Cardiovasculaire (Paris, France), Bourse Marc Laskar.

Dr. Mongardon received consultant fees from Amomed (Vienna, Austria). Dr. Gaudard received payment from Abiomed (Aachen, Germany), Air Liquide Santé (Gentilly, France), and Abbot (Chicago, Illinois) and consultancy fees from Amomed. Dr. Matthay received payment for his institution from Roche-Genentech (San Francisco, California), from Citius Pharmaceuticals (Cranford, New Jersey) for consulting for ARDS trial design, from Novartis (Bâle, Switzerland) for consulting for ARDS trial design, and from Johnson & Johnson (New Brunswick, New Jersey) and Pliant Therapeutics (San Francisco, California) for ARDS consultation. The other authors declare no competing interests.

What is COVID-19?

The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: Preparation for severe respiratory emergency outbreaks

Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome

Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1)

Extracorporeal membrane oxygenation for pandemic influenza A(H1N1)-induced acute respiratory distress syndrome

Extracorporeal membrane oxygenation for respiratory failure

Extracorporeal life support for adults with acute respiratory distress syndrome

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Elbourne D; CESAR Trial Collaboration: Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial

Groupe de Recherche Clinique en REanimation et Soins Intensifs du Patient en Insuffisance Respiratoire aiguE (GRC-RESPIRE) Sorbonne Université; Paris-Sorbonne ECMO-COVID Investigators: Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: A retrospective cohort study

Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: A multicenter descriptive study

Extracorporeal membrane oxygenation for critically ill patients with COVID-19-related acute respiratory distress syndrome: Worth the effort?

Extracorporeal membrane oxygenation for patients with COVID-19 in severe respiratory failure

Extracorporeal Life Support Organization: Extracorporeal membrane oxygenation support in COVID-19: An international cohort study of the Extracorporeal Life Support Organization registry

STOP-COVID Investigators: Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19

Utilisation de l'ECMO Lors de la Prise en Charge des Patients COVID-19

Leprince P; Paris ECMO-COVID-19 investigators: Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: A multicentre cohort study

Physiologic analysis and clinical performance of the ventilatory ratio in acute respiratory distress syndrome

Robust causal inference using directed acyclic graphs: The R package "DAGitty

Association of left ventricular ejection fraction and symptoms with mortality after elective noncardiac surgery among patients with heart failure

Driving pressure and transpulmonary pressure: How do we guide safe mechanical ventilation?

Impact of body mass index on outcomes following critical care

Left ventricular systolic function and inpatient mortality in patients hospitalized with coronavirus disease 2019 (COVID-19)

Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure: The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score

Meta-analysis Global Group in Chronic Heart Failure (MAGGIC): The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: An individual patient data meta-analysis

Trajectories of hospitalization in COVID-19 patients: An observational study in France

The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Outcome of acute respiratory distress syndrome patients treated with extracorporeal membrane oxygenation and brought to a referral center

Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring

Impact of high dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia

Bacterial infections in critically ill patients with SARS-2-COVID-19 infection: Results of a prospective observational multicenter study

Venovenous extracorporeal membrane oxygenation devices-related colonisations and infections

Retrieval of severe acute respiratory failure patients on extracorporeal membrane oxygenation: Any impact on their outcomes?

Public Assistance-Hospitals of Paris

collected data, provided and cared for study patients Martin Dres

Public Assistance-Hospitals of Paris

Hospital of Saint-Brieuc

University Hospital of Saint-Denis

University Hospital of Rennes, Rennes, France, provided and cared for study patients Alessandro Parasido

University Hospital of Strasbourg